Altea, Amylin, Eli Lilly deal

Altea granted Lilly and Amylin exclusive, worldwide rights to develop and commercialize transdermal exenatide

Read the full 140 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE